MSB 2.91% $1.06 mesoblast limited

Mesoblast on TV right now., page-9

  1. 5,487 Posts.
    lightbulb Created with Sketch. 8940
    Hi Hodgsop,

    Nice pick up, and the media attention around Mesoblast a copule of years ago was not just in Australia, but in the US as well. See below:



    Although these stories were run run a couple of years ago across two different continents... it does highlight two important things for Mesoblast:

    1. There is an un-met need and Mesoblast have a product in the making that will be regarded as the 'holy grail' of lower back-pain treatment.

    2. It takes a lot of money and a very very long time from inception, research, development, trial, trail again, and trial again, to finally filing for approval for commercial sale. We are talking almost a decade from inception to a product such as MPC-06-ID is made ready for commercial sale. This is a significant barrier to entry and Mesoblast has no other known competitor that can offer the same level of efficacy (or even close) for this un-met need.

    When the programs were made around 2 years ago, we were getting results for phase 2 trials. We are now almost 2 years on and the first Phase 3 trials will be commencing end of 2016 (have been recruiting since Mar15), with a finish date of December 2017 (12 month effectiveness trial).

    See below for details of the trial.

    Phase 3 trials MPC-06-ID

    The pipe-line for MSB has always been amazing, but what is exciting is that the pipe-line is not only growing, but the value inflextion points of existing products are getting very very close. With CHF phase 3 trial IA results this quarter, and the updated timetable to be released. CHF could be stopped early if overwhelming efficacy is demonstrated ... so watch this space!
    Last edited by stockrock: 26/04/16
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.